-
Mashup Score: 5
Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD 1, Antje Hoering, PhD 2, Parameswaran Hari, MBBS, MD 3, Rachael Sexton, PhD 2 * and Robert Z. Orlowski, MD, PhD 4 1 City of Hope Medical Center, Duarte, CA 2 SWOG Statistical Center, Seattle, WA 3 Division of Hematology and Oncology, Department of Medicine, Medical College of
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11
Program: Oral and Poster Abstracts Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III Hematology Disease Topics & Pathways: Research, Adult, Epidemiology, Clinical Research, Health outcomes research, Education, Diseases, Real-world evidence, Myeloid Malignancies, Study Population, Human 1 Morsani College of Medicine, University of South Florida, Tampa, FL 2 H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 3 Department of Malignant Hematology, H. Lee Moffitt
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
At #ASH24, Ziad Abuhelwa, MD (@zabuhelwa) discusses a retrospective analysis of the outcomes of a large cohort of MDS patients to compare outcomes between IDH1-MT and wild-type. Read more: https://t.co/pL3aNqTTF8 @ASH_hematology #ASH24 https://t.co/IyebaSFPpl
-
-
Mashup Score: 6
Program: Oral and Poster Abstracts Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III Hematology Disease Topics & Pathways: Research, Adult, Translational Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Plasma Cell Disorders, Diseases, Immune mechanism, Biological therapies, Treatment Considerations, Lymphoid Malignancies, Computational biology, Biological Processes, Study Population, Human Praneeth Reddy Sudalagunta, PhD 1 *, David R. Noyes, MS 2 *,
Source: ash.confex.comCategories: General Medicine News, Onc News and JournalsTweet-
Join Praneeth Reddy Sudalagunta, PhD at #ASH24 as he presents the differential effects of bridging therapy on the immune microenvironment and outcomes with idecabtagene-vicleucel in multiple myeloma. Read more: https://t.co/148u07T4t4 @ASH_hematology #MoffittASH24 https://t.co/BIWku7TiPA
-
-
Mashup Score: 9
Program: Oral and Poster Abstracts Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster III Hematology Disease Topics & Pathways: Research, Clinical Research, Real-world evidence Abida Babu, MBBS 1, Kathryn Bower, MD 2 *, Madiha Siraj, MD 3 *, Biwei Cao, MS 4 *, Jongphil Kim, PhD 2 *, Hany Elmariah, MD, MS 5, Rawan Faramand, MD 5, Sayeef Mirza, MD, MPH 5, Lia Perez, MD 5 *, Asmita Mishra, MD, MBA 5, Farhad Khimani, MD 5 *, Jose L. Ochoa-Bayona, MD 1 *,
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
Join Abida Babu, MBBS as she discusses the effect of fludarabine and melphalan educed-intensity conditioning in comparison to fludarabine and busulfan myeloablative on allogeneic hematopoietic cell transplantation in AML in complete remission. Read more: https://t.co/ZN57Hqmz3w… https://t.co/wQhFMOFsrG https://t.co/bbm0yiAQYb
-
-
Mashup Score: 8Paper: Reprogramming CLL T-Cell Mitochondrial Fitness Using PI3K Inhibition for Enhancing CAR T-Cell Therapy - 3 day(s) ago
Program: Oral and Poster Abstracts Session: 702. CAR-T Cell Therapies: Basic and Translational: Poster III Hematology Disease Topics & Pathways: Fundamental Science, Research, Translational Research, Immunology, Metabolism, Biological Processes, Molecular biology 1 Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 2 Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 3 Department of Experimental Immunology, Amsterdam
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
Tomorrow at #ASH24, Wael Gamal, PhD presents on reprogramming chronic lymphocytic leukemia T-cell mitochondrial fitness using PI3K inhibition for enhancing CAR T-cell therapy. Read more: https://t.co/EKeIL0Fd08 @ASH_hematology #MoffittASH24 https://t.co/TIxHXw0SPq
-
-
Mashup Score: 4
Program: Oral and Poster Abstracts Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III Hematology Disease Topics & Pathways: Clinical trials, ALL, Adult, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Adverse Events Bijal D Shah, MD 1, Jeremy Pantin, MD 2 *, Karamjeet S Sandhu, MD 3, Elias Jabbour, MD 4, Jae H. Park, MD 5, Paul Shaughnessy, MD 6, Mehrdad Abedi, MD 7 *, Michael R Bishop, MD 8, Daniel J. DeAngelo, MD, PhD 9, Wolfram Brugger, MD 10 *, Martin
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
At #ASH24, Bijal Shah, MD discusses the healthcare resource utilization and costs associated with managing CRS and ICANS in patients with relapsed /refractory adult B-cell acute lymphoblastic leukemia receiving obecabtagene autoleucel. Read more 👉https://t.co/yVMHcQ79Fl… https://t.co/RTW8QtbuuB https://t.co/poQq3iWrnp
-
-
Mashup Score: 7
Program: Oral and Poster Abstracts Session: 619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Poster III Hematology Disease Topics & Pathways: Clinical trials, Research, Clinical Research, Measurable Residual Disease 1 Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 2 Malignant Hematology Department, Moffitt Cancer Center, Tampa, FL 3 Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL 4
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
At #ASH24, David Sallman, MD discusses a prospective evaluation of the impact of measurable residual disease by error corrected next-generation sequencing with CPX-351 in acute myeloid leukemia. Read more: https://t.co/GLeORd6xQR @ASH_hematology #MoffittASH24 https://t.co/3J0NWpxwSL
-
-
Mashup Score: 12
Program: Oral and Poster Abstracts Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III Hematology Disease Topics & Pathways: Adult, Clinical Practice (Health Services and Quality), Drug development, Treatment Considerations, Study Population, Human, Measurable Residual Disease Nelli Bejanyan, MD 1, Hany Elmariah, MD, MS 1, Jongphil Kim, PhD 2 *, Cheryl Cox 3 *, Melissa Lowden 4 *, Xiaofei Song, PhD 2 *, Hien Liu, MD 5, Bin Yu 6 *, Kayla Reid, MS 7 *, Sean J.
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
At #ASH24, Nelli Bejanyan, MD presents the findings of a first-in-human trial using expanded donor gamma delta T cell immunotherapy to prevent acute myeloid leukemia relapse after allogeneic transplantation. Read more: https://t.co/YEXVvJ01c6 @ASH_hematology #MoffittASH24 https://t.co/a91Z9fga0h
-
-
Mashup Score: 8Paper: Patterns of Progression and Outcomes in Multiple Myeloma after Anti-BCMA CAR T-Cell Therapy - 3 day(s) ago
Program: Oral and Poster Abstracts Session: 653. Multiple Myeloma: Clinical and Epidemiological: Poster III Hematology Disease Topics & Pathways: Research, Adult, Clinical Research, Health outcomes research, Plasma Cell Disorders, Diseases, Real-world evidence, Lymphoid Malignancies, Study Population, Human 1 H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 2 Morsani College of Medicine, University of South Florida, Tampa, FL 3 Department of Hematology and Oncology, USF Morsani/H. Lee
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
Tomorrow at #ASH24, join Ziad Abuhelwa, MD (@zabuhelwa) as he highlights the progression patterns and outcomes in multiple myeloma after anti-BCMA CAR T-cell therapy. Read more: https://t.co/e5sQM4t6fO @ASH_hematology #MoffittASH24 https://t.co/dTrXdeLGzF
-
-
Mashup Score: 9
Program: Oral a nd Poster Abstracts Session: 908. Outcomes Research: Myeloid Malignancies: Poster III Hematology Disease Topics & Pathways: Clinical Practice (Health Services and Quality), Diversity, Equity, and Inclusion (DEI) 1 Department of Oncological Sciences, H. Lee Moffitt Cancer Center, University of South Florida, ALBANY, NY 2 Department of Oncological Sciences, H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL 3 H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 4
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
During #ASH24, Faustine Ong, MD (@faustine_ong) discusses disparities in AML survival in the targeted therapy era. Read more: https://t.co/9vtwS7WPUc @ASH_hematology #MoffittASH24 https://t.co/h2WZUDUCZj
-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/zV0OvcDZWf